Drug Development

Takeda rests its R&D footprint on U.S. hubs 

Back in late 2014, when Takeda announced that it had recruited Sanofi vet Andrew Plump as head of its R&D group, savvy observers were careful to note that Plump would be based in the Japanese company’s Boston hub. A few days ago, the Japanese pharma company unveiled its $725 million plan to reorganize R&D, pulling out of Cambridge, UK while concentrating much of the work in the Boston area. This chart from Takeda helps illustrate what’s going on in R&D, as the pharma company looks to expand on its links in the key hub while keeping San Diego in play for industry connections on the West Coast. Clearly, much of its future collaborative work will be done in the U.S. as CEO Christophe Weber methodically moves to change the culture at Takeda.

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy